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Abstract
Background: Chronic hepatitis C virus (HCV) infection results from weak or absent T cell
responses. Pegylated-interferon-alpha (IFN-α) and ribavirin, the standard of care for chronic HCV,
have numerous immune effects but are not potent T cell activators. A potent immune activator
such as TLR9 agonist CpG oligodeoxynucleotide (CpG) may complement current treatment
approaches.
Methods: Peripheral blood mononuclear cells (PBMC) obtained from HCV chronic carriers who
failed previous treatment and from healthy donors were incubated in vitro with the three main CpG
classes (A, B or C), recombinant IFN-α-2b (IntronA) and/or ribavirin. Proliferation and cytokine
secretion (IFN-α, IL-10 and IP-10) were evaluated.
Results: CpG induced proliferation and cytokine secretion in patterns expected for each CpG
class with similar group means for HCV and healthy donors. IntronA and ribavirin, alone or
together, had no detectable effects. IntronA and C-Class CpG together induced more IFN-α than
CpG alone in most subjects. IFN-α secretion was proportional to the number of plasmacytoid
dendritic cells in PBMC from healthy donors but not HCV donors in whom responses were highly
heterogeneous.
Conclusion: The strong immune stimulatory effect of CpG on PBMC isolated from treatment-
failed HCV patients suggests possible utility alone or in combination with current HCV antiviral
treatment.
Background
Hepatitis C virus (HCV)-induced liver disease is an impor-
tant health issue [1,2]. Acute infection usually is not spon-
taneously cleared in part due to immune escape by
emerging quasispecies [3] and virus-induced immune
dysfunction. HCV-specific Th1-type immune responses,
which are considered essential for longterm viral control
and eradication [4,5] are stronger and broader in those
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who go on to develop chronic disease [6-9]. These
responses improve during therapy but remain much
weaker than with self-resolving infection [10-12]. This
suggests that the relatively poor response (< 50% for gen-
otype 1) achieved with pegylated-interferon-alpha (PEG-
IFN-α) and ribavirin[13] may be due to inadequate
immune stimulation. PEG-IFN-α and ribavirin both
appear to possess anti-viral and some immune modula-
tory activities [14,15]. Although the mechanism of ribavi-
rin activity remains unresolved this medication may
enhance virological and biochemical responses that are
associated with faster second phase viral decay with con-
sequent accelerated reduction in the pool of infected cells
[16-19]. Ribavirin activity may be mediated by reduced T
cell production of IL-10 [20-22]. IL-10 has been proposed
to promote the formation of regulatory T cells (Treg) in
chronic HCV that inhibit the generation of desirable Th1
type T cell responses [23]. However, neither PEG-IFN-α
nor ribavirin appear to be a potent immune stimulators
[24,25]. As such, HCV treatments may benefit from more
potent immune modulators used alone or in combination
with current treatment regimes.
Toll-like receptors (TLR) expressed by immune cells recog-
nize specific pathogen-associated patterns, and play a crit-
ical role in regulating innate and adaptive immunity
[26,27]. Synthetic oligodeoxynucleotides (ODN) contain-
ing immunostimulatory CpG motifs (CpG) directly acti-
vate human B cells and plasmacytoid dendritic cells
(pDC) through TLR9 [28]. Other immune cells are indi-
rectly activated. CpG has potential utility in HCV via mul-
tiple mechanisms of viral control. These include
activation of natural killer (NK) cells which clear virus
from infected hepatocytes during acute infection [29-31],
pDC maturation for improved antigen presentation, and
enhanced Th1 cytokine profiles (IL-12, IFN-γ and many
IFN-α subtypes) that have known antiviral properties and
promote Th1-biased lytic and non-lytic T cell responses
[32]. This former property is observed even in the pres-
ence of pre-existing Th2 responses [33].
CpG properties vary depending on length, sequence,
backbone and formation of secondary or tertiary struc-
tures. Three main classes of stimulatory CpG are described
[34]. A-Class CpG is synthesized with a chimeric back-
bone with nuclease resistant phosphorothioate 5' and 3'
ends and a native phosphodiester central CpG motif
region. These molecules form higher ordered structures
and are characterized by strong NK cell and pDC activa-
tion, high levels of IFN-α production, and limited B cell
activation [35-38]. B-Class CpG are phosphorothioate
throughout and do not form secondary structures. They
are characterized by strong B cell activation [39], moder-
ate NK activation [29], and pDC activation with moderate
IL-12 and limited IFN-α production. C-Class CpG are
phosphorothioate molecules with a 3' palindrome region
that permits stem-loops and duplexes. They have proper-
ties intermediate to A- and B-Classes with good B cells and
NK cells activation, and induce DC IFN-α secretion
[38,40,41]. The higher order structures of A- and C-
Classes appear to affect intracellular localization and facil-
itate cross-linking of TLR9 receptors, which may be asso-
ciated with IFN-α induction.
A B-Class CpG has entered clinical testing and has demon-
strated efficacy together with doublet chemotherapy in a
Phase II study in non-small cell lung cancer [manuscript
submitted] and as a hepatitis B vaccine adjuvant [42] in
healthy volunteers [43,44] and vaccine hyporesponsive
HIV-infected patients [45]. Based on this knowledge, we
evaluate the ability of different CpG classes to stimulate
immune cells from healthy or HCV-infected donors to
proliferate and secrete key cytokines.
Methods
Human PBMC
Peripheral blood mononuclear cells (PBMC) were recov-
ered from 27 adult volunteers (12 healthy, 15 HCV treat-
ment refractory) at The Ottawa Hospital, Ottawa, Canada
under informed consent and IRB approval. Subjects with
other chronic infections or who had received HCV therapy
within 3 months were excluded. Viral genotypes for the 15
HCV-infected subjects was: 1b (n = 6), 1a (n = 5), 3a (n =
3) and 4c (n = 1). PBMC were purified from whole blood
(200 ml, venous puncture, heparinized vacutainers) by
centrifugation over Ficoll-Pacque (Amersham Pharmacia
Biotech, Uppsala, Sweden) at 400 × g for 35 min. Cells
were resuspended in RPMI complete media containing
10% normal human AB serum (heat inactivated) and 1%
penicillin/streptomycin at 10 × 106/ml and used fresh to
assay cytokine secretion and proliferation.
Reagents
ODN sequences were: A-Class CpG (2336;
GGG*G*A*C*G*A*C*G*T*C*G*T*C*GGGGGG), B-
Class CpG (2006; TCGTCGTTTTGTCGTTTTGTCGTT), C-
Class CpG (2429; TCGTCGTTTTCGGCGGCCGCCG) and
non-CpG control (4010 ; TGCTGCTTTTTGCT-
GGCTTTTT). B- and C-Class CpG had entire nuclease
resistant phosphorothioate backbones. A-Class CpG had
chimeric backbone with central phosphodiester region
(indicated by *) and phosphorothioate ends. All ODN,
verified to be endotoxin-free (Coley Pharmaceutical
GmbH; Langenfeld, Germany), were resuspended in TE
buffer at pH 8.0 (OmniPur®; EM Science, Gibbstown,
USA) and diluted in RPMI 1640 complete media (Gibco-
BRL, Grand Island, USA) containing 10% heat inacti-
vated, normal human AB serum (Wisent, St. Bruno,Page 2 of 9
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prior to use in cell assays.
Phytohemagglutinin (Sigma-Aldrich, Oakville, Canada),
positive control in cell stimulation assays, was diluted in
media then added to cells for final concentration of 10 μg/
ml.
IntronA (Schering, Pointe-Claire, Canada) was added to
the culture media for final concentrations of 125 or 1000
IU/ml. Ribavirin (CN Biosciences, La Jolla, USA) was
reconstituted to 500 μM with sterile distilled water then




Freshly isolated PBMC (1 × 106 in 200 μl complete RPMI
media) were incubated at 37°C with 5% CO2 in 96-well
flat-bottom plates with ODN at 3 or 6 μg/ml (approxi-
mately 0.5 and 1 μM). Cell supernatants collected after 48
hrs were stored at -80°C until assayed. Media alone and
PHA were negative and positive controls respectively.
Commercial ELISA kits were used according to manufac-
turer instructions to measure IP-10, IL-10 (R&D Systems,
Minneapolis, USA) and multi-species human-IFN-α (PBL
Biomedical Laboratories, Piscataway, USA). The kit speci-
fied detection limits were used for ELISA values below
these limits (16, 23 and 31 pg/ml for IP-10, IL-10 and
IFN-α respectively).
Preliminary dose-response data for CpG on PBMC from 3
healthy donors cultured with C-Class (1, 3, 6, 9 and 12
μg/ml final concentration) and B-Class (1, 3, and 6 μg/
ml) CpG showed maximum responses 3 μg/ml for IFN-α
and at 6 μg/ml (B-Class) or 12 μg/ml (C-Class) for IP-10
and BCP levels. Due to blood volume limitations, CpG
was tested only at 3 and 6 μg/ml for B- and C-Classes
(approximately 0.5 and 1 μM respectively) and 6 μg/ml
for the A-Class.
Flow cytometric analysis of pDC in freshly isolated PBMC fr m healthy (ope  circles, n = 12) and HCV-infected (grey or bla k triangles,  = 15) donors; HCV don rs with low vi al load at baseli e (< 600,000 IU/ml) are indicated by grey t i nglesigur  2
Flow cytometric analysis of pDC in freshly isolated PBMC 
from healthy (open circles, n = 12) and HCV-infected (grey 
or black triangles, n = 15) donors; HCV donors with low 
viral load at baseline (< 600,000 IU/ml) are indicated by grey 
triangles. Numbers of pDC counted among 50,000 events by 
flow cytometry of lineage negative, CD11c negative, HLA-
DR+, BDCA4+ cells are plotted against the amount of IFN-α 
secreted by 1× 106 cells cultured for 48 hrs in the presence 
of the C-Class CpG at 6 μg/ml. Each point represents the 
results for an individual subject (average of duplicate assays).Levels of cytokines secreted by PBMC from healthy (n = 9 to 12) or HCV-infected (n = 13 to 15) don rs after 48 hr cul-ture with media, recombinant IFN-alpha ( IFN-α, 125 IU/ml),ribavi in (RBV, 5 μM), o -CpG control ODN, A-Class, BClass or -Class CpG (all ODN at 6 μg/ml)Figure 1
Levels of cytokines secreted by PBMC from healthy (n = 9 to 
12) or HCV-infected (n = 13 to 15) donors after 48 hr cul-
ture with media, recombinant IFN-alpha (rIFN-α, 125 IU/ml), 
ribavirin (RBV, 5 μM), non-CpG control ODN, A-Class, B-
Class or C-Class CpG (all ODN at 6 μg/ml). White bars 
(Healthy) and black bars (HCV), show mean values and 
standard error of the means for each group of subjects. The 
lowest limit of quantification for each of the parameters was 
as follows: IFN-α, 31.2 pg/ml, IL-10, 23.4 pg/ml and IP-10, 7.8 
pg/ml.Page 3 of 9
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ODN solutions (100 μl) were added to 96 well plates to
give final concentrations of 3 or 6 μg/ml. Isolated PBMC
were resuspended at 1 × 106/ml in complete RPMI media
and 100 μl of cells were added to each well and cultured
for 5 days at 37°C with 5% CO2. Cells were pulsed with
3H-thymidine (1 μCi/well) for 18 h then harvested onto
filter paper; radioactivity was measured and reported as a
stimulation index (SI) relative to untreated media control.
Identification of pDC by flow cytometry
Three-colour immunofluorescent flow cytometric analysis
was used to quantify pDC. 3 × 106 PBMC were resus-
pended in 300 μl of complete RPMI media and divided
among three tubes, one as negative control (autofluores-
cence), and two for pDC detection of lineage negative,
CD11c negative, HLA-DR positive, and either BDCA-4
positive or CD123 positive. Monoclonal antibodies were:
Mouse IgG1 Anti-Human BDCA-4-PE (Miltenyi Biotech,
Auburn, USA), Mouse IgG1 Anti-Human CD123-PE (BD
Biosciences-Pharmingen, San Diego, USA). Mouse Anti-
Human CD11c-PC5 (BeckmanCoulter, Fullerton, USA),
Mouse IgG1 Anti-Human HLA-DR-ECD (BeckmanCoul-
ter) and a FITC-conjugated mouse IgG1, IgG2b anti-
human lineage cocktail including CD3, CD14, CD16,
CD19, CD20, CD56 (BD Biosciences-Pharmingen). Stain-
ing was per manufacturer recommendations; analysis by
flow cytometry counted 50,000 events per sample (Beck-
man Coulter Epics XL-MCL, Expo32 software).
Epstein Barr Virus immortalized B-cell lines
Healthy PBMC from 5 donors were resuspended in 2.5 ml
of RPMI media (5 × 106 cells) containing 10% fetal bovine
serum (GibcoBRL) and 1% penicillin/streptomycin.
Epstein-Barr virus (EBV)-containing supernatant (2.5 ml)
previously collected from a EBV transformed B cell line
(B95-8, ATCC, Manassas, USA) per manufacturer instruc-
tions was mixed with PBMC and incubated 2 hr at 37°C
with 5% CO2. Cyclosporin A (Sigma-Aldrich) at 1 μg/ml
in RPMI complete media was added to a final volume of
10 ml and cells were grown 4 wk in flasks at 37°C with 5%
CO2.
Statistical analysis
Data were expressed as group means ± standard errors of
the means (SEM) for absolute data. Student's t test was
used to compare two groups and one-factor analysis of
variance (ANOVA) followed by the Mann Whitney Test
for three groups or more.
Proliferative responses in PBMC from healthy (open circles, n = 10 to 12) or HCV-infected (filled circles, n = 10 to 15) donors after incubation with A-, B- or C-Class CpG (6 μg/ml), posi c ntrol PHA (10 μg/ml) or non-CpG control ODN (6 μg/ml) f r 5 days, hen pulsing wi 3H-thym dinefor 6 t  8 h ursFigu e 4
Proliferative responses in PBMC from healthy (open circles, 
n = 10 to 12) or HCV-infected (filled circles, n = 10 to 15) 
donors after incubation with A-, B- or C-Class CpG (6 μg/
ml), positive control PHA (10 μg/ml) or non-CpG control 
ODN (6 μg/ml) for 5 days, then pulsing with 3H-thymidine 
for 16 to 18 hours. Horizontal bars represent the group 
means for stimulation indices (SI = cpm with PHA or ODN/
cpm with media alone).
Correlation of blood levels of HCV RNA and levels of IFN-α sec eted per pDC from individual HCV-infected donors (n =15)Figur  3
Correlation of blood levels of HCV RNA and levels of IFN-α 
secreted per pDC from individual HCV-infected donors (n = 
15). The amount of IFN-α secreted by 1 × 106 cells cultured 
for 48 hrs with A-Class (black symbols) or C-Class (white 
symbols) CpG (6 μg/ml) was divided by the number of pDC 
(lineage negative, CD11c negative, HLA-DR+ and BDCA4+), 
counted among 50,000 events by flow cytometry and plotted 
against HCV RNA levels for the same subjects.Page 4 of 9
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Cytokine secretion
Healthy donor PBMC secreted the highest levels of IFN-α
and IP-10 (Figure 1). Consistent with a previous report,
secretion was greatest with A-Class, less with C-Class, and
least with B-Class CpG [38]. HCV PBMC yielded results
similar to that of healthy PBMC for B- and C-Classes but
produced significantly less IFN-α (p = 0.02) and a trend to
less IP-10 with A-Class CpG. All CpG classes induced sim-
ilar IL-10 levels in healthy and HCV PBMC (Figure 1).
Two methods were used to quantify pDC in CD11c nega-
tive, HLA-DR positive cells: (i) BDCA-4 detection, which
is specific to pDC but may be down-regulated upon pDC
activation leading to concerns regarding undercounting,
and (ii) CD123 detection, which is also expressed on
basophils [46] [N.B. basophils are negative for HLA-DR].
Both methods yielded similar numbers of pDC from
healthy (73 ± 42 and 56 ± 27 respectively, mean ± SD of
50,000 events) and HCV-infected (66 ± 30 and 58 ± 23)
donors. Linear regression demonstrated a good correla-
tion between number of pDC (BDCA-4 analysis) and
amount of IFN-α secreted in response to C-Class CpG for
normal donors (R2 = 0.76). This was not identified in
HCV donors (R2 = 0.06) although a better correlation (R2
= 0.43) was observed for HCV subjects with low blood
levels of HCV RNA (< 600,000 IU/ml) (Figure 2). Simi-
larly, A- and B-Class CpG stimulated IFN-α secretion that
was well correlated with the number of pDC in normal
(R2 = 0.50 or 0.51 respectively) but not HCV (R2 = 0.04 or
0.09) PBMC (not shown). The amount of IFN-α produced
per pDC varied widely with HCV PBMC and did not cor-
relate with viral RNA blood levels (Figure 3).
PBMC proliferation
Under the culture conditions used, CpG-induced PBMC
proliferation is thought to be mostly B cell related [47]. As
previously reported [38], proliferation of PBMC from
healthy donors was weak with A-Class but strong with B-
and C-Class CpG. B- and C-Classes had similar effects at
high concentration (~1 μM) (Figure 4) but at low concen-
tration (~0.5 μM) the B-Class was more potent (p < 0.03,
not shown). The non-CpG control ODN caused some
proliferation, which is attributed to the weak TLR9-
dependent stimulation of cells by the phosphorothioate
backbone [48]. This was greater than that seen with the A-
Class chimeric backbone (p = 0.0023). There were no sig-
nificant differences in the proliferative responses between
PBMC from healthy and HCV-infected subjects with any
of the three classes of CpG (p > 0.05).
Effects of IntronA and ribavirin
As expected, IP-10 was induced by IntronA (Figure 1). The
amount was similar to that with B-Class but significantly
less than with A- or C-Class CpG (p < 0.002). IntronA did
not induce proliferative responses (data not shown) or IL-
10 secretion (Figure 1).
The IFN-α ELISA assay does not differentiate between
exogenous and endogenous forms. To determine whether
IntronA induced IFN-α secretion from pDC we used EBV-
immortalized B cell lines. These cells have IFN-α receptors
but do not produce IFN-α which allows for the amount of
IntronA remaining after 48 hr culture to be estimated. Sev-
enteen experiments adding IntronA (125 IU/ml) to five
different B-cell lines for 48 hr gave a mean level over
media background of 172 ± 81 pg/ml. This was deemed to
be a better estimate than measuring IFN-α after spiking
media with IntronA (319 ± 112 pg/ml, n = 13) since met-
abolic degradation by cultured cells was expected.
Amounts of IFN-α in supernatants of HCV or healthy
PBMC and B-cell lines cultured with IntronA were similar
(p < 0.05) indicating IntronA does not induce significant
IFN-α secretion (Figure 5).
Ribavirin alone or in combination with IntronA did not
induce significant IFN-α secretion (Figure 5). Ribavirin
Levels of IFN-α secreted by PBMC from healthy (n = 9 to 12) or HCV-infected (n = 13 to 15) don rs after 48 hr cul ure with recombinant IFN-α (rIFN-α, 125 IU/ml), ribavirin (RBV,5 μM), rIFN-α plus ribavirin, C Class CpG (6 μg/ml) or CpGplus rIFN-αFigu  5
Levels of IFN-α secreted by PBMC from healthy (n = 9 to 12) 
or HCV-infected (n = 13 to 15) donors after 48 hr culture 
with recombinant IFN-α (rIFN-α, 125 IU/ml), ribavirin (RBV, 
5 μM), rIFN-α plus ribavirin, C-Class CpG (6 μg/ml) or CpG 
plus rIFN-α. Horizontal black bars show group mean values, 
and numbers of subjects (n) in each group are indicated 
below the X-axis. The background level of IFN-α deemed to 
be contributed by the added rIFN-α alone, as measured in 
control B-cell line experiments (334 pg/ml), is shown by the 
hatched line.Page 5 of 9
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1).
IntronA combined with CpG
IntronA combined with C-Class CpG significantly aug-
mented the amount of IFN-α secreted relative to CpG
alone (p < 0.02) (Figure 5). Individual data revealed a
greater than 50% increase over CpG alone for all donors
tested.
All (12/12) healthy and most (13/15) HCV donors
achieved a minimum 50% increase and 4/12 and 3/15
produced a minimum 100% increase in IFN-α secretion
over CpG alone with addition of Intron A (Figure 6). Syn-
ergy did not correlate with HCV genotype or viral RNA
level (R2 < 0.2) (Figure 7); both of these viral characteris-
tics influence therapeutic response [18,49,50].
No augmentation was seen for CpG-induced IP-10 or IL-
10 or PBMC proliferation (data not shown). It is possible
that CpG alone induced maximal IP-10 and hence no
additive effects were noted despite higher levels of IFN-α.
A similar phenomenon with IFN-α and IP-10 induction
by B-Class CpG has been described [51].
Discussion
Recognition of the need to overcome immune dysfunc-
tion in chronic HCV and induce strong virus-specific T cell
responses has led to the evaluation of immune modula-
tors alone and in combination with current HCV thera-
pies. We demonstrated CpG-induced PBMC stimulation
in both healthy and HCV-infected donors. Of note, high
level IFN-α secretion by pDC was produced following A-
and C-Class CpG induction [32],
A-Class CpG induce very high amounts of IFN-α secretion
from pDC [37,52]. We found diminished IFN-α levels
with chronic HCV compared to healthy donor PBMC.
This is consistent with a number of earlier studies of A-
Class CpG on PBMC [53-55] or purified pDC [56]. One
study with purified pDC study failed to reveal a difference
[57]. In the present study, lower IFN-α secretion in those
with HCV cannot be explained by reduced pDC numbers
since IFN-α levels and pDC numbers did not correlate.
One previous study identified similar levels of IFN-α in
healthy and HCV pDC [54]. Reduced IFN-α secretion was
attributed to reduced numbers of circulating pDC. In
another study, levels of IFN-α per pDC were lower with
HCV [55]. A greater than one hundred-fold reduced
capacity in IFN-α production was attributed to immature
phenotype and compartmentalization of pDC in the
inflamed liver [55]. It is note worthy that in our evalua-
tion PBMC stimulation with B- or C-Class CpG produced
no differences in proliferation and cytokine secretion
Correlation of blood levels of HCV RNA and levels of IFN-α sec eted by PBMC from individual HCV-infected donors (n =15) af r 48 hr culture with A-Class (black symbo )  C-lass (white symb ls) CpG (6 μg/ml)Figur  7
Correlation of blood levels of HCV RNA and levels of IFN-α 
secreted by PBMC from individual HCV-infected donors (n = 
15) after 48 hr culture with A-Class (black symbols) or C-
Class (white symbols) CpG (6 μg/ml). The 7 HCV subjects 
with low viral load (< 600,000 IU/ml) had R2 values of 0.07 
and 0.005 for the A- and C-Class CpG respectively.
Percent change in amount of IFN-α secreted by PBMC after 48 hr culture with rIFN-α (125 IU/ml) plus C-Class CpG (6 μg/ml) ove  that with CpG aloneFigure 6
Percent change in amount of IFN-α secreted by PBMC after 
48 hr culture with rIFN-α (125 IU/ml) plus C-Class CpG (6 
μg/ml) over that with CpG alone. The amount of IFN-α 
measured for rIFN-α alone for each subject was subtracted 
from the rIFN-α plus CpG value to account for rIFN-α itself 
remaining in the culture media. Individual data is shown for 
PBMC from healthy (open bars, n = 12) or HCV-infected 
(closed bars, n = 15) donors.Page 6 of 9
(page number not for citation purposes)
Journal of Immune Based Therapies and Vaccines 2008, 6:3 http://www.jibtherapies.com/content/6/1/3between health volunteers and HCV-infected study partic-
ipants.
Structural differences between A- and C-Class CpG may
account for variable IFN-α secretion outcomes. Mono-
meric molecules such as B-Class CpG can activate TLR9
but only the A- and C-Classes that form higher ordered
structures can induce high levels of IFN-α secretion from
pDC. This may be a consequence of cross-linkage with
TLR9 receptors [38]. A-Class CpGs form large polymeric
structures due to their poly-G regions whereas C-Class
only form dimers. It has been proposed that pDC revert to
a more immature state with chronic HCV infection [55] or
that direct HCV infection of pDC may alter their ability to
take up and/or respond to the larger A-Class structures
[58].
HCV chronic carriers have dysfunctional pDC with
impaired capacity to stimulate allogeneic T cells. This may
be mediated by altered MHC expression and cytokine pro-
duction that facilitate regulatory T cells development
[56,59-61]. Reduced IFN-α secretion has been noted in
response to a non-specific stimulus such as the herpes
simplex virus [6] and poly(I:C), a TLR3 ligand [53]. As
such, the ability of both A- and C-Class CpG to induce
IFN-α secretion in PBMC from HCV chronic carriers is
notable. IFN-α secretion with C-Class CpG stimulation
were similar between healthy donors and HCV infected
participants but levels were more variable in the latter
group. As a consequence, there was good correlation
between the amount of IFN-α secreted and number of
pDC in the sample for healthy PBMC but not in the HCV
population.
A- and C-Class CpG produced similar levels and types of
immune activation with the exception of B-cell prolifera-
tion which is more robust following C-Class stimulation.
Both were more potent than B-Class. Based on these
results, and earlier findings of stronger TLR9-dependent
NFkB signaling with C-Class [38], a C-Class CpG (CPG
10101) was chosen for clinical testing in HCV in combi-
nation with PEG-IFN-α and/or ribavirin. Thus, our evalu-
ation of the interactions between these medications and
CpG in HCV-infected donor PBMC stimulation tests is rel-
evant. As observed in other studies [25], IntronA and/or
ribavirin had limited effect on the immune parameters
tested. This suggests that these medications may be subop-
timal for inducing T cell responses thought to prevent
virological relapse following HCV antiviral therapy. Com-
bining IntronA with C-Class CpG augmented IFN-α secre-
tion from pDC. This is consistent with other work
suggesting that pre-treatment of human PBMC with
recombinant IFN-α primes pDC to respond to the stimu-
latory effects of bacterial DNA [62]. Even thought no rib-
avirin-CpG synergy was detected in the present in vitro
study, such synergy might be realized in vivo. In vivo eval-
uation has demonstrated that ribavirin may diminish Th2
cytokines including IL-10 thereby enhancing Th1
responses [21] and reducing regulatory T cell induction
[63]. Blocking the IL-10 receptor on HCV PBMC results in
increased HCV-specific IFN-γ producing T cells [23].
Hence, ribavirin might enhance in vivo responses to CpG
by perturbing IL-10 activity.
Conclusion
In summary, the C-Class of CpG molecules possess effec-
tive immunostimulatory effects on PBMC from chronic
HCV donors and might provide complementary and addi-
tional mechanisms of action to current HCV therapies.
Authors' contributions
CC participated in study design, was responsible for study
recruitment and manuscript preparation, NA, SE and JV
conducted the analysis and contributed to the manuscript
preparation, AK and HD conceived of the study, partici-
pated in study design and manuscript preparation. All
authors have read and approved the final manuscript.
Acknowledgements
We are grateful to Isabelle Sequin and Diane Cote, clinical study nurses at 
The Ottawa Hospital, and Sonja McAuley, Clinical Research Associate at 
Coley Pharmaceutical Group for their assistance in obtaining phlebotomy 
samples and Kathleen Myette for technical assistance in performing the 
assays.
References
1. Hughes CA, Shafran SD: Chronic hepatitis C virus manage-
ment: 2000-2005 update.  Ann Pharmacother 2006, 40:74-82.
2. McHutchison JG, Bacon BR: Chronic hepatitis C: an age wave of
disease burden.  Am J Manag Care 2005, 11:S286-95; quiz S307-11.
3. Marrone A, Sallie R: Genetic heterogeneity of hepatitis C virus.
The clinical significance of genotypes and quasispecies
behavior.  Clin Lab Med 1996, 16:429-449.
4. Kanto T, Hayashi N: Immunopathogenesis of hepatitis C virus
infection: multifaceted strategies subverting innate and
adaptive immunity.  Intern Med 2006, 45:183-191.
5. Thimme R, Lohmann V, Weber F: A target on the move: innate
and adaptive immune escape strategies of hepatitis C virus.
Antiviral Res 2006, 69:129-141.
6. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G:
Impaired allostimulatory function of dendritic cells in
chronic hepatitis C infection.  Gastroenterology 2001,
120:512-524.
7. Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L,
Houghton M, Walker BD, Koziel MJ: Liver-derived CTL in hepa-
titis C virus infection: breadth and specificity of responses in
a cohort of persons with chronic infection.  J Immunol 1998,
160:1479-1488.
8. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner
AJ, Choo QL, Shuster JR, Kuo G, Bonino F, et al.: T-lymphocyte
response to hepatitis C virus in different clinical courses of
infection.  Gastroenterology 1993, 104:580-587.
9. Koziel MJ: The role of immune responses in the pathogenesis
of hepatitis C virus infection.  J Viral Hepat 1997, 4 Suppl 2:31-41.
10. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY: Intrahepatic
hepatitis C virus-specific cytotoxic T lymphocyte activity and
response to interferon alfa therapy in chronic hepatitis C.
Hepatology 1998, 28:225-230.
11. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW: Peginterferon
alone or with ribavirin enhances HCV-specific CD4 T-helperPage 7 of 9
(page number not for citation purposes)
Journal of Immune Based Therapies and Vaccines 2008, 6:3 http://www.jibtherapies.com/content/6/1/31 responses in patients with chronic hepatitis C.  Gastroenterol-
ogy 2002, 123:1070-1083.
12. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV:
Hepatitis C virus-specific T-cell reactivity during interferon
and ribavirin treatment in chronic hepatitis C.  Gastroenterology
2000, 118:346-355.
13. Pawlotsky JM: Therapy of hepatitis C: from empiricism to
eradication.  Hepatology 2006, 43:S207-20.
14. Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I inter-
ferons (alpha/beta) in immunity and autoimmunity.  Annu Rev
Immunol 2005, 23:307-336.
15. Dixit NM, Perelson AS: The metabolism, pharmacokinetics and
mechanisms of antiviral activity of ribavirin against hepatitis
C virus.  Cell Mol Life Sci 2006, 63:832-842.
16. Gish RG: Treating HCV with ribavirin analogues and ribavi-
rin-like molecules.  J Antimicrob Chemother 2006, 57:8-13.
17. Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams
R, Zeuzem S, Naoumov NV: Relationship between early HCV
kinetics and T-cell reactivity in chronic hepatitis C genotype
1 during peginterferon and ribavirin therapy.  J Hepatol 2005,
43:776-782.
18. Scott LJ, Perry CM: Interferon-alpha-2b plus ribavirin: a review
of its use in the management of chronic hepatitis C.  Drugs
2002, 62:507-556.
19. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S: Effect of riba-
virin on hepatitis C viral kinetics in patients treated with
pegylated interferon.  Hepatology 2003, 37:1351-1358.
20. Barnes E, Salio M, Cerundolo V, Medlin J, Murphy S, Dusheiko G,
Klenerman P: Impact of alpha interferon and ribavirin on the
function of maturing dendritic cells.  Antimicrob Agents Chemother
2004, 48:3382-3389.
21. Martin J, Navas S, Quiroga JA, Pardo M, Carreno V: Effects of the
ribavirin-interferon alpha combination on cultured periph-
eral blood mononuclear cells from chronic hepatitis C
patients.  Cytokine 1998, 10:635-644.
22. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T:
Ribavirin polarizes human T cell responses towards a Type 1
cytokine profile.  J Hepatol 1999, 30:376-382.
23. Rigopoulou EI, Abbott WG, Williams R, Naoumov NV: Direct evi-
dence for immunomodulatory properties of ribavirin on T-
cell reactivity to hepatitis C virus.  Antiviral Res 2007, 75:36-42.
24. Feld JJ, Hoofnagle JH: Mechanism of action of interferon and rib-
avirin in treatment of hepatitis C.  Nature 2005, 436:967-972.
25. Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T,
Janosch A, Schetter C, Krieg AM: Immunopharmacology of CpG
oligodeoxynucleotides and ribavirin.  Antimicrob Agents Chem-
other 2004, 48:2314-2317.
26. Creagh EM, O'Neill LA: TLRs, NLRs and RLRs: a trinity of path-
ogen sensors that co-operate in innate immunity.  Trends
Immunol 2006, 27:352-357.
27. Iwasaki A, Medzhitov R: Toll-like receptor control of the adap-
tive immune responses.  Nat Immunol 2004, 5:987-995.
28. Krieg AM: Therapeutic potential of Toll-like receptor 9 acti-
vation.  Nat Rev Drug Discov 2006, 5:471-484.
29. Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in
murine and human cells by CpG motifs in oligodeoxynucle-
otides and bacterial DNA.  J Immunol 1996, 157:1840-1845.
30. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto
I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL,
Krieg AM: Delineation of a CpG phosphorothioate oligodeox-
ynucleotide for activating primate immune responses in
vitro and in vivo.  J Immunol 2000, 164:1617-1624.
31. Sivori S, Carlomagno S, Moretta L, Moretta A: Comparison of dif-
ferent CpG oligodeoxynucleotide classes for their capability
to stimulate human NK cells.  Eur J Immunol 2006, 36:961-967.
32. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho
S, Antonenko S, Liu YJ: The nature of the principal type 1 inter-
feron-producing cells in human blood.  Science 1999,
284:1835-1837.
33. Racila DM, Kline JN: Perspectives in asthma: molecular use of
microbial products in asthma prevention and treatment.  J
Allergy Clin Immunol 2005, 116:1202-1205.
34. Vollmer J: TLR9 in health and disease.  Int Rev Immunol 2006,
25:155-181.
35. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A,
Vicari A, Trinchieri G: Type I interferon dependence of plasma-
cytoid dendritic cell activation and migration.  J Exp Med 2005,
201:1157-1167.
36. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM: Differential
and competitive activation of human immune cells by dis-
tinct classes of CpG oligodeoxynucleotide.  J Leukoc Biol 2002,
71:813-820.
37. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas
ZK, Endres S, Krieg AM, Hartmann G: Identification of CpG oli-
gonucleotide sequences with high induction of IFN-alpha/
beta in plasmacytoid dendritic cells.  Eur J Immunol 2001,
31:2154-2163.
38. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M,
Wader T, Tluk S, Liu M, Davis HL, Krieg AM: Characterization of
three CpG oligodeoxynucleotide classes with distinct immu-
nostimulatory activities.  Eur J Immunol 2004, 34:251-262.
39. Bernasconi NL, Onai N, Lanzavecchia A: A role for Toll-like recep-
tors in acquired immunity: up-regulation of TLR9 by BCR
triggering in naive B cells and constitutive expression in
memory B cells.  Blood 2003, 101:4500-4504.
40. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow
N, Rothenfusser S, Endres S: Rational design of new CpG oligo-
nucleotides that combine B cell activation with high IFN-
alpha induction in plasmacytoid dendritic cells.  Eur J Immunol
2003, 33:1633-1641.
41. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J,
Coffman RL, Van Nest G: Identification of a novel CpG DNA
class and motif that optimally stimulate B cell and plasmacy-
toid dendritic cell functions.  J Leukoc Biol 2003, 73:781-792.
42. Krieg A, Davis H: CpG ODN as a TH1 immune enhancer for
prophylactic and therapeutic vaccines.  In: Hackett CJ, Harn DA,
eds Vaccines Adjuvants: Immunological and Clinical Principles Humana
Press Inc 2005:87-110.
43. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM,
Cameron DW, Heathcote J: CPG 7909, an immunostimulatory
TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-
B HBV vaccine in healthy adults: a double-blind phase I/II
study.  J Clin Immunol 2004, 24:693-701.
44. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ: A
phase I study of the safety and immunogenicity of recom-
binant hepatitis B surface antigen co-administered with an
immunostimulatory phosphorothioate oligonucleotide adju-
vant.  Vaccine 2003, 21:2461-2467.
45. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg
AM, Cameron DW: CPG 7909 adjuvant improves hepatitis B
virus vaccine seroprotection in antiretroviral-treated HIV-
infected adults.  Aids 2005, 19:1473-1479.
46. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck
DW, Schmitz J: BDCA-2, BDCA-3, and BDCA-4: three mark-
ers for distinct subsets of dendritic cells in human peripheral
blood.  J Immunol 2000, 165:6037-6046.
47. Yi AK, Hornbeck P, Lafrenz DE, Krieg AM: CpG DNA rescue of
murine B lymphoma cells from anti-IgM-induced growth
arrest and programmed cell death is associated with
increased expression of c-myc and bcl-xL.  J Immunol 1996,
157:4918-4925.
48. Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Pay-
ette P, Davis HL, Schetter C, Krieg AM: Oligodeoxynucleotides
lacking CpG dinucleotides mediate Toll-like receptor 9
dependent T helper type 2 biased immune stimulation.
Immunology 2004, 113:212-223.
49. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL
Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A,
Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection.  N Engl J Med 2002, 347:975-982.
50. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Rein-
dollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginter-
feron alfa-2b plus ribavirin compared with interferon alfa-2b
plus ribavirin for initial treatment of chronic hepatitis C: a
randomised trial.  Lancet 2001, 358:958-965.
51. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, Wullner M,
Tluk S, Hartmann H, Kritzler A, Muller C, Schetter C, Krieg AM:
CpG oligodeoxynucleotides stimulate IFN-gamma-inducible
protein-10 production in human B cells.  J Endotoxin Res 2004,
10:431-438.Page 8 of 9
(page number not for citation purposes)
Journal of Immune Based Therapies and Vaccines 2008, 6:3 http://www.jibtherapies.com/content/6/1/3Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
52. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM: Human
peripheral blood cells differentially recognize and respond to
two distinct CPG motifs.  J Immunol 2001, 166:2372-2377.
53. Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman
MM, Lehmann PV, Valdez H: Selective impairments in dendritic
cell-associated function distinguish hepatitis C virus and HIV
infection.  J Immunol 2004, 172:4907-4916.
54. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML: Normal
functional capacity in circulating myeloid and plasmacytoid
dendritic cells in patients with chronic hepatitis C.  J Infect Dis
2005, 192:497-503.
55. Ulsenheimer A, Gerlach JT, Jung MC, Gruener N, Wachtler M, Back-
mund M, Santantonio T, Schraut W, Heeg MH, Schirren CA, Zachoval
R, Pape GR, Diepolder HM: Plasmacytoid dendritic cells in
acute and chronic hepatitis C virus infection.  Hepatology 2005,
41:643-651.
56. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T,
Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N:
Reduced numbers and impaired ability of myeloid and plas-
macytoid dendritic cells to polarize T helper cells in chronic
hepatitis C virus infection.  J Infect Dis 2004, 190:1919-1926.
57. Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F,
Ciccorossi P, Zorat F, Pozzato G, Comar C, Abrignani S, Wack A:
Comparable functions of plasmacytoid and monocyte-
derived dendritic cells in chronic hepatitis C patients and
healthy donors.  J Hepatol 2005, 42:61-67.
58. Goutagny N, Fatmi A, De Ledinghen V, Penin F, Couzigou P,
Inchauspe G, Bain C: Evidence of viral replication in circulating
dendritic cells during hepatitis C virus infection.  J Infect Dis
2003, 187:1951-1958.
59. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M: Decreased
interferon-alpha production and impaired T helper 1 polari-
zation by dendritic cells from patients with chronic hepatitis
C.  Clin Exp Immunol 2004, 137:559-565.
60. Szabo G, Dolganiuc A: Subversion of plasmacytoid and myeloid
dendritic cell functions in chronic HCV infection.  Immunobiol-
ogy 2005, 210:237-247.
61. Tsubouchi E, Akbar SM, Horiike N, Onji M: Infection and dysfunc-
tion of circulating blood dendritic cells and their subsets in
chronic hepatitis C virus infection.  J Gastroenterol 2004,
39:754-762.
62. Vallin H, Perers A, Alm GV, Ronnblom L: Anti-double-stranded
DNA antibodies and immunostimulatory plasmid DNA in
combination mimic the endogenous IFN-alpha inducer in
systemic lupus erythematosus.  J Immunol 1999, 163:6306-6313.
63. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL,
Thornton AM: The lifestyle of naturally occurring CD4+
CD25+ Foxp3+ regulatory T cells.  Immunol Rev 2006, 212:60-73.Page 9 of 9
(page number not for citation purposes)
